Form 4 for RGNX REGENXBIO Inc.
Accepted 2024-02-16 00:00:00 ET · period of report 2024-02-14 · accession 0001562180-24-001395 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2024-02-16 | 2024-02-14 | RGNX | Mills Kenneth T. | Pres, CEO, Dir | M - OptEx | $3.76 | +15.0K | 423.0K | +4% | +$56.4K |
| DMT | 2024-02-16 | 2024-02-14 | RGNX | Mills Kenneth T. | Pres, CEO, Dir | S - Sale+OE | $16.75 | -15.0K | 418.4K | -3% | -$251.3K |
| DT | 2024-02-16 | 2024-02-14 | RGNX | Mills Kenneth T. | Pres, CEO, Dir | M - OptEx | $0.00 | -15.0K | 126.4K | -11% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-14 | M | A | 15,000 | $3.76 | 423,035 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-14 | S | D | 10,348 | $16.88 | 408,035 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $16.78 to $17.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 3 | Common | Common Stock | 2024-02-14 | S | D | 4,652 | $16.47 | 418,383 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $15.78 to $16.77. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 4 | Derivative | Stock Options (Right to Buy) | 2024-02-14 | M | D | 15,000 | $0.00 | 126,354 | D | $3.76 · — to 2025-05-19 | 15,000 Common Stock | (F4) The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. |